BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.

  title={BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.},
  author={Jos{\'e} Miguel S{\'a}nchez-Torres and Santiago Viteri and Miguel {\'A}ngel Molina and Rafael Rosell},
  journal={Translational lung cancer research},
  volume={2 3},
Inhibitors targeting active protein kinases, such as EGFR or ALK, have demonstrated significant efficacy in the treatment of lung cancer. Activating mutations in the MAPK pathway, which includes the enzymes RAS, RAF, MEK, and ERK, result in constitutive signalling, leading to oncogenic cell proliferation and escape from apoptosis; therefore this pathway is a focus of crucial interest for the development of cancer drugs. In melanoma, the most commonly mutated gene is BRAF, with mutations usually… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 13 extracted citations


Publications referenced by this paper.
Showing 1-10 of 38 references

Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion

  • R Straussman, T Morikawa, K Shee
  • Nature 2012;487:500-4
  • 2013
1 Excerpt

BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma

  • U Trefzer, D Minor, A Ribas
  • Pigment Cell Res 2011;24:abstr LBA1-1
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…